Discovery of a potent tubulin polymerization inhibitor: Synthesis and evaluation of water-soluble prodrugs of benzophenone analog

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 21, 2010, Pages 6327-6330

  Lee, Jaekwang ^a   Bae, Suyeal ^a   Lee, Seo Hee ^a   Choi, Hojin ^a   Kim, Young Hoon ^a   Kim, Soo Jin ^a   Park, Gyu Tae ^a   Moon, Seung Kee ^a   Kim, Dal Hyun ^a   Lee, Sungsook ^a   Ahn, Soon Kil ^b   Choi, Nam Song ^a   Lee, Kyung Joo ^a  

^a Chong Kun Dang Research Institute   (South Korea)

^b SolarLight Ltd   (South Korea)

Author keywords

Antitumor activity; Aqueous solubility; Inhibitor; Prodrug; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOPHENONE DERIVATIVE; CKD 516; PRODRUG; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; SOLUBILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPHENONES; CELL PROLIFERATION; HL-60 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TUBULIN; TUBULIN MODULATORS; WATER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

RATTUS;

EID: 77956336496     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.05.060     Document Type: Article

References (33)

1. M.A. Jordan, and L. Wilson Nat. Rev. Cancer 4 2004 253 and references therein
2. R. Romagnoli, P.G. Baraldi, M.D. Carrion, O. Cruz-Lopez, C.L. Cara, G. Basso, G. Viola, M. Khedr, J. Balzarini, S. Mahboobi, A. Sellmer, A. Bramcale, and E. Hamel J. Med. Chem. 52 2009 5551
3. N. Sirisoma, S. Kasib, A. Pervin, H. Zhang, S. Jiang, A. Willardsen, M. Anderson, V. Baichwal, G.G. Mather, K. Jessing, R. Hussain, K. Hoang, C.M. Pleiman, B. Tseng, J. Drewe, and S.X. Cai J. Med. Chem. 51 2008 4771
4. J.-X. Duan, X. Cai, F. Meng, L. Lan, C. Hart, and M. Matteucci J. Med. Chem. 50 2007 1001
5. L. Wang, K.W. Woods, Q. Li, D. Frost, S.H. Rosenberg, and H.L. Sham J. Med. Chem. 45 2002 1697
6. P.G. Morris, and M.N. Fornier Expert Rev. Anticancer Ther. 9 2008 175
7. F. Meng, X. Cai, J. Duan, M.G. Matteucci, and C.P. Hart Cancer Chemother. Pharmacol. 61 2008 953
8. Y.-S. Wu, M.S. Coumar, J.-Y. Chang, H.-Y. Sun, F.-M. Kuo, C.-C. Kuo, Y.-J. Chen, C.-Y. Chang, C.-L. Hsiao, J.-P. Liou, C.-P. Chen, H.-T. Yao, Y.-K. Chiang, U.-K. Tan, C.-T. Chen, C.-Y. Chu, S.-Y. Wu, T.-K. Yeh, C.-Y. Lin, and H.-P. Hsieh J. Med. Chem. 52 2009 4941
9. P. Hinnen, and F. Eskens Br. J. Cancer 96 2007 1159
10. S. Kasibhatla, H. Gourdeau, K. Meerovitch, J. Drewe, S. Reddy, L. Qiu, H. Zhang, F. Bergeron, D. Bouffard, Q. Yang, J. Herich, S. Lamothe, S.X. Cai, and B. Tseng Mol. Cancer Ther. 3 2004 1365
11. D.M. Patterson, and G.J.S. Rustin Clin. Oncol. 19 2007 443
12. C. Gridelli, A. Rossi, P. Maione, M. Rossi, V. Castaldo, P.C. Sacco, and G. Volantuoni Oncologist 14 2009 612
13. J. Griggs, J.C. Metcalfe, and R. Hesketh Lancet Oncol. 2 2001 82
14. T.J. Kim, M. Ravoori, C.N. Landen, A.A. Kamat, L.Y. Han, C. Lu, Y.G. Lin, W.M. Merritt, N. Jennings, W.A. Spannuth, R. Langley, D.M. Gershenson, R.L. Coleman, V. Kundra, and A.K. Sood Cancer Res. 67 2007 9337
15. H. Waterbeemd, H. Lennaernas, and P. Artursson Drug Bioavailability R. Mannhold, H. Kubinyi, H. Timmerman, Methods and Principles in Medicinal Chemistry Vol. 18 2003 Wiley-VCH Weinheim 189 242
16. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Eur. J. Cancer 37 2001 1590
17. V.J. Stella, and K.W. Nti-Addae Adv. Drug Delivery Rev. 59 2007 677
18. T.D. Bradshaw, M.-S. Chua, V. Trapani, E.A. Sausville, and M.F.G. Stevens Br. J. Cancer 86 2002 1348
19. C.G. Wermuth C.G. Wermuth, The Practice of Medicinal Chemistry 3rd ed. 2008 Academic Press Burlington 721 746
20. S. Sobue, K. Tan, G. Layton, V. Leclerc, and A. Weil Br. J. Clin. Pharmacol. 57 2004 773
21. V.J. Stella Adv. Drug Delivery Rev. 19 1996 311
22. W. Plunkett, P. Huang, and V. Gandhi Semin. Oncol. Nurs. 17 1990 3
23. N.L. Pochopin, W.N. Charman, and V.J. Stella Drug Metab. Dispos. 22 1994 770
24. H. Bundgaard, C. Larsen, and P. Thorbek Int. J. Pharm. 18 1984 67
25. K. Vollmann, R. Qurishi, J. Hockemeyer, and C.E. Mueller Molecules 13 2008 348
26. Detailed SAR studies of 1 will be reported in a separate publication. J. Med. Chem., submitted for publication.
27. Lee, K. J.; Kim, S. J.; Park, G. T.; Han, B. H.; Choi, J. H.; Hwang, I.-C.; Lee, J.; Choi, H.; Kim, Y. H.; Kim, D.-H.; Lee, S.; Hong, C. I. Abstract of Papers, 100th American Association for Cancer Research (AACR), Denver, CO, 2009; Abstract 5561.
28. Kim, S. J.; Kim, S.-M.; Choi, J. H.; Lee, D. H.; Lee, D. W.; Park, G. T.; Lim, I.-T.; Jeon, D.-J.; Lee, S. W.; Kim, D.-H.; Lee, K. J.; Lee, S.; Hong, C. I. Abstract of Papers, 101th American Association for Cancer Research (AACR), Washington D.C., 2010; Abstract 4425.
29. ++1).
30. 2 atmosphere, cell viability was determined by addition of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, final concentration of 0.25 mg/ml).
31. K. Ohsumi, T. Hatanaka, R. Nakagawa, Y. Fukuda, Y. Morinaga, Y. Suga, Y. Nihei, K. Ohishi, Y. Akiyama, and T. Tsuji Anti-Cancer Drug Des. 14 1999 539
32. 3.
33. M.D. Coleman Human Drug Metabolism 2005 Wiley Bermingham Chapter 3